[Levodopa-carbidopa intestinal gel treatment introduced by surgical gastrostomy in a patient of Parkinson's disease after Billroth II gastrojejunostomy]

Rinsho Shinkeigaku. 2018 Sep 28;58(9):570-573. doi: 10.5692/clinicalneurol.cn-001150. Epub 2018 Aug 31.
[Article in Japanese]

Abstract

A 68-year-old man, who had received Billroth II gastrojejunostomy because of duodenal ulcer at the age of 20, was diagnosed to have Parkinson's disease at age 57 years. The drug therapy has been effective in the first 10 years, however, recently he was suffering from troublesome dyskinesia and wearing-off in spite of diligent drug adjustments. Although the indication of levodopa-carbidopa intestinal gel (LCIG) treatment was good, percutaneous endoscopic gastrostomy was difficult because of abdominal adhesion. Therefore, we introduced LCIG by surgical gastrostomy. After LCIG therapy, wearing-off and dyskinesia disappeared. This is the first case of Parkinson's disease patient with LCIG therapy by surgical gastrostomy in Japan.

Keywords: Parkinson’s disease; continuous dopaminergic stimulation; levodopa-carbidopa intestinal gel; percutaneous endoscopic gastrostomy; surgical gastrostomy.

MeSH terms

  • Aged
  • Antiparkinson Agents / administration & dosage*
  • Carbidopa / administration & dosage*
  • Dosage Forms
  • Drug Combinations
  • Drug Compounding
  • Duodenal Ulcer / surgery
  • Gastric Bypass*
  • Gastrostomy*
  • Gels
  • Humans
  • Levodopa / administration & dosage*
  • Male
  • Parkinson Disease / drug therapy*
  • Treatment Outcome

Substances

  • Antiparkinson Agents
  • Dosage Forms
  • Drug Combinations
  • Gels
  • carbidopa, levodopa drug combination
  • Levodopa
  • Carbidopa